Windtree Therapeutics, Inc. (NASDAQ:WINT) Sees Significant Drop in Short Interest

Windtree Therapeutics, Inc. (NASDAQ:WINT) saw a significant decline in short interest in the month of March. As of March 15th, there was short interest totalling 49,300 shares, a decline of 40.6% from the February 28th total of 83,000 shares. Based on an average daily volume of 2,640,000 shares, the short-interest ratio is presently 0.0 days. Currently, 6.6% of the company’s shares are sold short.

Windtree Therapeutics Stock Performance

Shares of Windtree Therapeutics stock opened at $1.56 on Friday. The stock has a 50 day moving average of $4.74 and a 200 day moving average of $33.14. The firm has a market capitalization of $1.17 million, a price-to-earnings ratio of -0.09 and a beta of 0.68. Windtree Therapeutics has a fifty-two week low of $1.45 and a fifty-two week high of $737.44.

Hedge Funds Weigh In On Windtree Therapeutics

A hedge fund recently bought a new stake in Windtree Therapeutics stock. Renaissance Technologies LLC bought a new stake in Windtree Therapeutics, Inc. (NASDAQ:WINT) during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 119,266 shares of the company’s stock, valued at approximately $42,000. Renaissance Technologies LLC owned about 1.08% of Windtree Therapeutics at the end of the most recent reporting period. 29.33% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Separately, HC Wainwright reissued a “neutral” rating and issued a $350.00 price target on shares of Windtree Therapeutics in a research note on Wednesday, December 4th.

Windtree Therapeutics Company Profile

Windtree Therapeutics, Inc, a biotechnology company, focuses on the development of therapeutics for the treatment of acute cardiovascular diseases. The company’s lead product candidate is istaroxime, which is in Phase 2b clinical trial for the treatment of acute decompensated heart failure, as well as for the treatment of early cardiogenic shock.